Published in Blood on August 01, 2013
The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Blood (2015) 1.69
Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter study. J Clin Oncol (2014) 1.39
Cancer-associated thrombosis: an overview. Clin Med Insights Oncol (2014) 1.23
Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev (2014) 1.07
Risk of ischemic stroke in patients with ovarian cancer: a nationwide population-based study. BMC Med (2014) 0.97
Risk of site-specific cancer in incident venous thromboembolism: a population-based study. Thromb Res (2014) 0.94
Pre-operative thrombotic complications of neoadjuvant chemotherapy for breast cancer: Implications for immediate breast reconstruction. Ann Med Surg (Lond) (2014) 0.90
Venous thrombosis and cancer: from mouse models to clinical trials. J Thromb Haemost (2015) 0.86
Survival analysis in hematologic malignancies: recommendations for clinicians. Haematologica (2014) 0.83
Real-Time Label-Free Embolus Detection Using In Vivo Photoacoustic Flow Cytometry. PLoS One (2016) 0.82
Risk marker associations with venous thrombotic events: a cross-sectional analysis. BMJ Open (2014) 0.80
Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis. Onco Targets Ther (2016) 0.80
Mutant IDH1 and thrombosis in gliomas. Acta Neuropathol (2016) 0.79
Melanoma growth effects on molecular clearance from tumors and biodistribution into systemic tissues versus draining lymph nodes. J Control Release (2015) 0.78
Procoagulant role of neutrophil extracellular traps in patients with gastric cancer. Int J Clin Exp Pathol (2015) 0.78
Risk factors for incident venous thromboembolism in active cancer patients: A population based case-control study. Thromb Res (2016) 0.77
Preoperative Plasma Fibrinogen Level as a Significant Prognostic Factor in Patients With Localized Renal Cell Carcinoma After Surgical Treatment. Medicine (Baltimore) (2016) 0.77
Proteinase-Activated Receptor 2 Is a Novel Regulator of TGF-β Signaling in Pancreatic Cancer. J Clin Med (2016) 0.77
Incidence and Risk Factors of Thromboembolism with Multiple Myeloma in the Presence of Death as a Competing Risk: An Empirical Comparison of Statistical Methodologies. Healthcare (Basel) (2016) 0.77
Risk of venous thromboembolism in cancer patients treated with epoetins or blood transfusions. Br J Clin Pharmacol (2016) 0.77
Superior sagittal sinus thrombosis as the initial presentation of renal cell carcinoma. Proc (Bayl Univ Med Cent) (2015) 0.76
Platelet count measured prior to cancer development is a risk factor for future symptomatic venous thromboembolism: the Tromsø Study. PLoS One (2014) 0.76
Complications Associated With Use of Long-Term Central Venous Catheters Among Commercially Insured Women With Breast Cancer. J Oncol Pract (2015) 0.75
Severe hepatic dysfunction is associated with venous thromboembolic events in phase 1 clinical trials. Thromb Res (2015) 0.75
Trousseau's syndrome in a patient with advanced stage gastric cancer. World J Gastroenterol (2015) 0.75
Impact of D-Dimer for Prediction of Incident Occult Cancer in Patients with Unprovoked Venous Thromboembolism. PLoS One (2016) 0.75
Spinal cord infarct as a presentation of cholangiocarcinoma with metastases. Ann Transl Med (2015) 0.75
Pulmonary embolism in non-brain tumor patients after surgery-a retrospective study in China. World J Surg Oncol (2017) 0.75
Weight Change and Risk of Venous Thromboembolism: The Tromsø Study. PLoS One (2016) 0.75
Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis. Thromb Res (2015) 0.75
Existing data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort. Clin Epidemiol (2015) 0.75
External Jugular Vein Thrombosis as a Sign of Metastatic Breast Cancer. J Breast Health (2013) (2017) 0.75
Risk of Ischemic Stroke in Patients With Gastric Cancer: A Nationwide Population-Based Cohort Study. Medicine (Baltimore) (2015) 0.75
Deficiency of superoxide dismutase impairs protein C activation and enhances susceptibility to experimental thrombosis. Arterioscler Thromb Vasc Biol (2015) 0.75
Effects of androgen-deprivation therapy on hypercoagulability in prostate cancer patients: A prospective, longitudinal study. Can Urol Assoc J (2017) 0.75
Targeting clotting proteins in cancer therapy - progress and challenges. Thromb Res (2016) 0.75
Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism. Haematologica (2016) 0.75
Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. Cancer Med (2016) 0.75
Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. Mol Cancer Ther (2016) 0.75
Hospital Variation and Patient Characteristics Associated With Vena Cava Filter Utilization. Med Care (2017) 0.75
Cancer-associated pathways and biomarkers of venous thrombosis. Blood (2017) 0.75
Identifying ischemic stroke associated with cancer: a multiple model derived from a case-control analysis. J Neurol (2017) 0.75
Tumor-Derived Exosomes Induce the Formation of Neutrophil Extracellular Traps: Implications For The Establishment of Cancer-Associated Thrombosis. Sci Rep (2017) 0.75
Venous thromboembolism prophylaxis for ambulatory cancer patients, can we do better? J Thromb Thrombolysis (2017) 0.75
Clinical significance of plasma D-dimer in ovarian cancer: A meta-analysis. Medicine (Baltimore) (2017) 0.75
Preliminary Investigations Showing Venous Thromboembolism Recurrence in Patients with Residual Venous Obstruction in Singaporean Population. Int J Angiol (2017) 0.75
Epidemiological and outcome data in Japanese patients with deep vein thrombosis with and without malignancy. Heart Vessels (2017) 0.75
FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence. Clin Transl Oncol (2017) 0.75
Genome Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality. Clin Cancer Res (2017) 0.75
Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology (2003) 3.41
Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA (2005) 3.04
Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc Natl Acad Sci U S A (2006) 2.65
Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients. Arch Intern Med (2009) 2.16
Contrast-induced acute kidney injury and clinical outcomes after intra-arterial and intravenous contrast administration: risk comparison adjusted for patient characteristics by design. Am Heart J (2013) 2.09
Impact of incident venous thromboembolism on risk of arterial thrombotic diseases. Circulation (2013) 2.04
Evidence for activation of tissue factor by an allosteric disulfide bond. Biochemistry (2006) 1.99
Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med (2013) 1.91
Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol (2004) 1.88
Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. Biotechniques (2007) 1.66
The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood (2011) 1.61
Association of mild to moderate chronic kidney disease with venous thromboembolism: pooled analysis of five prospective general population cohorts. Circulation (2012) 1.59
The effect of flight-related behaviour on the risk of venous thrombosis after air travel. Br J Haematol (2008) 1.50
The risk of venous thrombosis in individuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors. Blood (2013) 1.47
[Suspicion of pulmonary embolism: added value of CT depends on patient characteristics and referring individual]. Ned Tijdschr Geneeskd (2012) 1.45
Cutting edge: expression patterns of surface and soluble triggering receptor expressed on myeloid cells-1 in human endotoxemia. J Immunol (2004) 1.45
Fluid loss does not explain coagulation activation during air travel. Thromb Haemost (2008) 1.38
A case of thrombosis at high altitude. Thromb Haemost (2005) 1.38
Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol (2012) 1.33
Multisystem morbidity and mortality in Cushing's syndrome: a cohort study. J Clin Endocrinol Metab (2013) 1.32
Molecular mechanism of violacein-mediated human leukemia cell death. Blood (2004) 1.27
Risk factors for venous thrombosis - current understanding from an epidemiological point of view. Br J Haematol (2010) 1.16
Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica (2009) 1.15
Quantification of bias in direct effects estimates due to different types of measurement error in the mediator. Epidemiology (2012) 1.11
Confounding by Indication: Letter to the Editor. Am J Sports Med (2016) 1.05
Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development. Blood (2010) 1.04
Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders. J Cell Mol Med (2008) 1.03
Long-term survival in a large cohort of patients with venous thrombosis: incidence and predictors. PLoS Med (2012) 1.03
Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood (2008) 1.01
Inflammatory cytokines as risk factors for a first venous thrombosis: a prospective population-based study. PLoS Med (2006) 1.01
Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. Semin Thromb Hemost (2011) 1.00
Alternatively spliced tissue factor promotes breast cancer growth in a β1 integrin-dependent manner. Proc Natl Acad Sci U S A (2013) 1.00
Broadening the factor V Leiden paradox: pulmonary embolism and deep-vein thrombosis as 2 sides of the spectrum. Blood (2012) 0.99
Intramyocardial injection of autologous bone marrow-derived ex vivo expanded mesenchymal stem cells in acute myocardial infarction patients is feasible and safe up to 5 years of follow-up. J Cardiovasc Transl Res (2013) 0.97
Prophylactic implantable cardioverter-defibrillator treatment in the elderly: therapy, adverse events, and survival gain. Europace (2011) 0.97
Increasing levels of free thyroxine as a risk factor for a first venous thrombosis: a case-control study. Blood (2010) 0.96
Recurrent implantable cardioverter-defibrillator replacement is associated with an increasing risk of pocket-related complications. Pacing Clin Electrophysiol (2010) 0.94
Prospective study of homocysteine and MTHFR 677TT genotype and risk for venous thrombosis in a general population--results from the HUNT 2 study. Br J Haematol (2008) 0.93
Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients. Europace (2011) 0.93
Diversity and clinical impact of Acinetobacter baumannii colonization and infection at a military medical center. J Clin Microbiol (2010) 0.93
Hematologic variables and venous thrombosis: red cell distribution width and blood monocyte count are associated with an increased risk. Haematologica (2013) 0.92
Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. Int J Cancer (2013) 0.91
The absolute risk of venous thrombosis after air travel: a cohort study of 8,755 employees of international organisations. PLoS Med (2007) 0.91
Cardiac device infections are associated with a significant mortality risk. Heart Rhythm (2011) 0.90
Tissue factor-dependent chemokine production aggravates experimental colitis. Mol Med (2011) 0.89
Complete abolishment of coagulant activity in monomeric disulfide-deficient tissue factor. Blood (2011) 0.87
Influence of gender on ischemic times and outcomes after ST-elevation myocardial infarction. Am J Cardiol (2012) 0.87
Nonproteolytic properties of murine alternatively spliced tissue factor: implications for integrin-mediated signaling in murine models. Mol Med (2012) 0.85
High factor VIIa levels do not promote tumor metastasis. Thromb Haemost (2008) 0.85
Anthropometric measures of obesity and risk of venous thromboembolism: the Tromso study. Arterioscler Thromb Vasc Biol (2009) 0.85
Sex difference in risk of second but not of first venous thrombosis: paradox explained. Circulation (2013) 0.85
Venous thromboembolism increases the risk of atrial fibrillation: the Tromso study. J Am Heart Assoc (2014) 0.84
High hematocrit as a risk factor for venous thrombosis. Cause or innocent bystander? Haematologica (2010) 0.84
Tissue factor mutated at the allosteric Cys186-Cys209 disulfide bond is severely impaired in decrypted procoagulant activity. Blood (2010) 0.84
The spatial QRS-T angle in the Frank vectorcardiogram: accuracy of estimates derived from the 12-lead electrocardiogram. J Electrocardiol (2010) 0.84
Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention. Am J Cardiol (2013) 0.83
d-Asb11 is an essential mediator of canonical Delta-Notch signalling. Nat Cell Biol (2008) 0.83
Tissue factor isoforms in cancer and coagulation: may the best isoform win. Thromb Res (2012) 0.83
Murine tissue factor coagulant activity is critically dependent on the presence of an intact allosteric disulfide. Haematologica (2012) 0.83
A randomized comparison of 1-h sodium bicarbonate hydration versus standard peri-procedural saline hydration in patients with chronic kidney disease undergoing intravenous contrast-enhanced computerized tomography. Nephrol Dial Transplant (2014) 0.83
Acute and severe coagulopathy in adult mice following silencing of hepatic antithrombin and protein C production. Blood (2013) 0.83
Role of hemostatic factors on the risk of venous thrombosis in people with impaired kidney function. Circulation (2013) 0.83
Patients with early arthritis consume less alcohol than controls, regardless of the type of arthritis. Rheumatology (Oxford) (2013) 0.82
Increased risk of venous thrombosis in persons with clinically diagnosed superficial vein thrombosis: results from the MEGA study. Blood (2011) 0.82
Pulse wave velocity and flow in the carotid artery versus the aortic arch: effects of aging. J Magn Reson Imaging (2013) 0.82
Finding the origin of pulmonary emboli with a total-body magnetic resonance direct thrombus imaging technique. Haematologica (2012) 0.82
Heart healthy diet and risk of myocardial infarction and venous thromboembolism. The Tromsø Study. Thromb Haemost (2012) 0.82
Anticoagulant therapy of cancer patients: Will patient selection increase overall survival? Thromb Haemost (2015) 0.81
Tissue factor signaling: a multi-faceted function in biological processes. Front Biosci (Schol Ed) (2011) 0.80
Role of obesity in the etiology of deep vein thrombosis and pulmonary embolism: current epidemiological insights. Semin Thromb Hemost (2013) 0.79
Coagulation factor Xa drives tumor cells into apoptosis through BH3-only protein Bim up-regulation. Exp Cell Res (2007) 0.79
[Prevention of contrast-induced nephropathy: time for nuance and a new guideline]. Ned Tijdschr Geneeskd (2013) 0.79
Effect of elevated levels of coagulation factors on the risk of venous thrombosis in long-distance travelers. Blood (2008) 0.78
The increased risk of venous thromboembolism by advancing age cannot be attributed to the higher incidence of cancer in the elderly: the Tromsø study. Eur J Epidemiol (2014) 0.78
The incidence of venous thromboembolism in patients with overt hyperthyroidism: a retrospective multicentre cohort study. Thromb Haemost (2012) 0.78
Evolutionary conservation of the tissue factor disulfide bonds and identification of a possible oxidoreductase binding motif. J Thromb Haemost (2012) 0.78
Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism. J Thromb Thrombolysis (2015) 0.78
Surveillance of second-degree relatives from melanoma families with a CDKN2A germline mutation. Cancer Epidemiol Biomarkers Prev (2013) 0.78
Protease-activated receptor (PAR)2, but not PAR1, is involved in collateral formation and anti-inflammatory monocyte polarization in a mouse hind limb ischemia model. PLoS One (2013) 0.78
Early reperfusion therapy affects inducibility, cycle length, and occurrence of ventricular tachycardia late after myocardial infarction. Circ Arrhythm Electrophysiol (2011) 0.77
Activation of the canonical beta-catenin pathway by histamine. J Biol Chem (2003) 0.77
Risk of a recurrent cardiovascular event in individuals with type 2 diabetes or intermediate hyperglycemia: the Hoorn Study. Diabetes Care (2013) 0.77
Increased risk of CVD after VT is determined by common etiologic factors. Blood (2013) 0.77
Endogenous sex hormone levels in men are not associated with risk of venous thromboembolism: the Tromso study. Eur J Endocrinol (2009) 0.76
Driving restrictions after implantable cardioverter defibrillator implantation: an evidence-based approach. Eur Heart J (2011) 0.76
Levels of prolactin in relation to coagulation factors and risk of venous thrombosis. Results of a large population-based case-control study (MEGA-study). Thromb Haemost (2012) 0.76
The risk of venous thrombosis after air travel: contribution of clinical risk factors. Br J Haematol (2014) 0.76
Five-year clinical follow-up from the MISSION! Intervention Study: sirolimus-eluting stent versus bare metal stent implantation in patients with ST-segment elevation myocardial infarction, a randomised controlled trial. EuroIntervention (2012) 0.76
Physical activity and risk of venous thromboembolism. The Tromso study. Haematologica (2010) 0.76
Statins and Risk of Bleeding: An Analysis to Evaluate Possible Bias Due to Prevalent Users and Healthy User Aspects. Am J Epidemiol (2016) 0.76
Reply to letter to the editor by Koza et al. Am Heart J (2013) 0.75
In silico tissue factor analysis: a bit-to-bit comparison. Thromb Haemost (2003) 0.75
Travel and venous thrombosis: an exercise in thinking about bias. Ann Intern Med (2009) 0.75
Activated protein C plasma levels in the fasting and postprandial states among patients with previous unprovoked venous thromboembolism. Thromb Res (2011) 0.75
The ERIKA trial: still limited evidence on the efficacy of thromboprophylaxis after knee arthroscopy. Thromb Haemost (2016) 0.75
Exposure Opportunity: The Advantages of Including Men in Analyses of Female-Related Risk Factors. Am J Epidemiol (2017) 0.75
Pre-infarction angina predicts thrombus burden in patients admitted for ST-segment elevation myocardial infarction. EuroIntervention (2012) 0.75
Control of anticoagulation with VKAs: overestimation of median TTR when assessed by linear extrapolation: A comment. Thromb Haemost (2017) 0.75